MoonLake’s Durability Alpha Leak Could Force FDA Hand on HS BLA

The VELA data is a classic case of signal and noise. The core efficacy signal is undeniable, but the regulatory path just got messier.

The clear win is in VELA-1. There, sonelokimab delivered a statistically significant improvement with a delta to placebo of 17% on the primary HiSCR75 endpoint. That's a clean, positive result that validates the drug's mechanism in a key trial.

The noise comes from VELA-2. Here, the company's primary analysis strategy-using a composite estimator-failed to cross the statistical significance threshold. The delta to placebo of 9% was just shy of the cutoff (p=0.053). The culprit? An unexpectedly high placebo response rate, which created a regulatory ambiguity. This narrow miss is the hurdle for the 2026 Biologics License Application (BLA).

But the story doesn't end at Week 16. The durability signal from the Week 40 data is powerful. By then, 62% of patients treated with sonelokimab achieved HiSCR75, with up to 32% achieving HiSCR100. This shows the response isn't just a short-term pop; it's holding and even improving. That's the alpha leak MoonLake is banking on.

The bottom line: This is a qualified success. The mechanism works, and the long-term data is strong. But the regulatory noise from VELA-2's composite endpoint miss means MoonLake will need to engage regulators aggressively to argue that the totality of evidence-including the robust Week 40 durability and the treatment policy strategy results-supports approval. Watch for those regulatory talks later this year.

The Competitive Edge & Regulatory Path

The durability advantage is MoonLake's biggest weapon. While competitors report HiSCR75 rates of roughly 40-60% at the one-year mark, MoonLake's sonelokimab is already at 62% at Week 40. That's a clear differentiation. The drug isn't just hitting a benchmark; it's exceeding it early and showing continued improvement. This positions sonelokimab as a potential durability leader in a crowded IL-17 HS market.

The regulatory path is getting a boost for another indication. The FDA has granted Fast Track designation for sonelokimab in palmoplantar pustulosis (PPP) based on Phase 2 data. This isn't just a formality. It means more frequent, efficient FDA interactions for the upcoming Phase 3 program, potentially enabling a faster development and review timeline. It's a signal that regulators see promise and are willing to engage early.

But the real test is for the HS BLA in the second half of 2026. The VELA-2 composite endpoint miss created ambiguity. The Fast Track for PPP shows the agency's willingness to engage, but MoonLake still needs to convert that into clarity for the HS application. The company must use the upcoming 52-week data and the totality of evidence-including the strong durability signal-to convince regulators that the Week 16 noise doesn't undermine the overall case. The bottom line: MoonLake has a clear competitive edge in durability and a regulatory efficiency boost for PPP. The executable strategy now hinges on locking down that HS BLA submission with a narrative that turns the Week 40 data into a regulatory certainty, not just a clinical win. Watch for the 52-week readout and the company's regulatory messaging in the coming months.

The Market Reaction & Financial Runway

The stock's reaction to the data is a classic case of short-term noise overwhelming long-term signal. MoonLake's shares are down roughly 58% over the past year, trading near $17 today. That's a brutal drawdown that reflects the market's patience wearing thin. Yet, the recent Phase 2 success in axial spondyloarthritis and the durability alpha leak from VELA-1 are the exact catalysts that could flip this narrative. The current price creates a potential entry point for those betting on the long-term franchise story.

The financial runway is the critical buffer that makes this bet possible. The company is burning cash at a steep rate, with a full-year 2025 net loss of $227.32 million. That's the reality of a pre-revenue biotech funding its pipeline. But crucially, MoonLake has enough powder to keep fighting. Management has stated it has sufficient cash to fund operations into the second half of 2027. That's a clear timeline-over 18 months of runway-to resolve the regulatory uncertainty from VELA-2, run the upcoming 52-week analysis, and prepare for the 2026 BLA submission.

The bottom line is a high-risk, high-reward setup. The stock's deep decline prices in failure, but the cash position provides the time needed for success. The risk is that the regulatory path proves longer or more costly than anticipated. The reward is a potential blockbuster franchise if MoonLake can successfully argue that the totality of evidence, anchored by the durability signal, overcomes the Week 16 noise. For now, the financial runway turns this from a speculative gamble into a timed bet. Watch the company's cash burn and regulatory engagement over the next year to see if the runway holds.

Catalysts & Watchlist: What to Monitor

The thesis is now a timed bet. Here's the watchlist for investors: the near-term events that will either validate the durability alpha leak or expose the regulatory noise.

1. Regulatory Engagement Clarity for the HS BLA (H2 2026): This is the single biggest catalyst. The FDA has confirmed the clinical evidence strategy for the planned BLA submission in the second half of 2026. The key now is for MoonLake to translate that confirmation into concrete regulatory clarity. Investors need to see the company lock down its submission package, using the totality of evidence-including the powerful Week 40 durability data-to overcome the Week 16 composite endpoint ambiguity. Watch for the company's regulatory messaging and any updates from the upcoming 52-week analysis. This is the make-or-break event for the 2026 timeline.

2. Phase 3 Design & Regulatory Feedback for the axSpA Program: The Phase 2 success in axial spondyloarthritis (axSpA) is a major pipeline win. The next step is Phase 3. Investors should monitor for details on the Phase 3 design and, crucially, any formal regulatory feedback from the FDA on that plan. Positive feedback would signal that regulators are engaged and supportive, potentially accelerating the entire rheumatology program. This could be a secondary catalyst that de-risks the broader franchise story and adds another potential revenue stream.

3. Cash Burn & Financial Runway Updates: The cash position is the fuel for this race. The company has sufficient cash to fund operations into the second half of 2027, but that runway is being burned. Watch for quarterly updates on cash burn and any announcements regarding manufacturing scale-up or partnership deals. A partnership could provide a cash infusion and shared development risk, while any deviation from the stated cash runway timeline would be a red flag. The financial runway turns this into a timed bet, so monitoring this is non-negotiable.

The bottom line: The watchlist is clear. The regulatory clarity for the HS BLA is the primary event. The axSpA Phase 3 design is a secondary catalyst. And the cash burn is the constant constraint. For investors, the path forward is to monitor these three pillars for signals that the durability alpha leak is being recognized as a regulatory certainty, not just a clinical curiosity.